Results 211 to 220 of about 355,625 (242)

Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.

Vaccine, 2018
H. Rinta-Kokko, A. Palmu, K. Auranen, J. Nuorti, M. Toropainen, Lotta, Siira, Mikko J. Virtanen, H. Nohynek, J. Jokinen   +9 more
semanticscholar   +1 more source

Childhood Deaths Attributable to Invasive Pneumococcal Disease in England and Wales, 2006–2014

Clinical Infectious Diseases, 2017
G. Oligbu, S. Collins, C. Sheppard, N. Fry, M. Slack, R. Borrow, S. Ladhani   +6 more
semanticscholar   +1 more source

Inhibition of T Cells Provides Protection against Early Invasive Pneumococcal Disease

, 2010
Kim S. LeMessurier, Hans Häcker, Elaine Tuomanen, Vanessa Redecke   +3 more
openalex   +1 more source

Invasive Pneumococcal Disease in HIV-Infected Adults

, 2011
Joaquín Burgos, María Luz Pintos Peñaranda, Antoni Payeras, Aroa Villoslada Gelabert, Adrián Curran, Margarita Garau, Melcior Riera, Manuel Crespo, Jordi Navarro, Eva Van den Eynde, Ana María Planes, Esteban Ribera, Albert Pahissa, Vicenç Falcó   +13 more
openalex   +1 more source

Immunogenicity of DTaP-IPV-Hib and MenC vaccines in the UK when administered with a 13-valent pneumococcal conjugate vaccine

, 2008
Baker, S., Daniels, E., Dymond, S., Faust, S.N., Finn, A., Galiza, E., Gruber, W., Heath, P.T., John, T., Klinger, C., Layton, H., Pestridge, S., Pollard, A., Scott, D., Snape, M., Tansey, S.   +15 more
core  

Some of the next articles are maybe not open access.

Related searches:

Nationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era.

Clinical Infectious Diseases, 2020
BACKGROUND Introduction of pneumococcal conjugate vaccines (PCVs) has shown a marked reduction in the disease caused by vaccine serotypes in children providing herd protection to the elderly group.
S. de Miguel, Mirian Domenech, F. González-Camacho, Julio Sempere, D. Vicioso, J. Sanz, Luis García Comas, C. Ardanuy, A. Fenoll, J. Yuste   +9 more
semanticscholar   +1 more source

Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence

Expert Review of Vaccines, 2021
Introduction: Routine pneumococcal vaccination for adults aged ≥60 or ≥65 years and those with underlying at-risk and high-risk conditions is recommended in many countries.
M. Niederman, Temitope A Folaranmi, U. Buchwald, L. Musey, A. Cripps, Kelly D Johnson   +5 more
semanticscholar   +1 more source

Changes in invasive pneumococcal disease spectrum after 13 valent pneumococcal conjugate vaccine implementation.

Clinical Infectious Diseases, 2019
BACKGROUND Pneumococcal conjugate vaccine (PCV) implementation has led to a sharp decrease in invasive pneumococcal disease (IPD) due to the reduction in PCV serotypes (VTs).
C. Levy, E. Varon, N. Ouldali, S. Béchet, S. Bonacorsi, R. Cohen   +5 more
semanticscholar   +1 more source

Prevalence of Immunodeficiency in Children With Invasive Pneumococcal Disease in the Pneumococcal Vaccine Era: A Systematic Review.

JAMA pediatrics, 2019
Importance Despite increasing access to vaccination, invasive pneumococcal disease (IPD) is responsible for approximately 826 000 deaths worldwide in children younger than 5 years each year.
Coen T Butters, L. Phuong, T. Cole, A. Gwee   +3 more
semanticscholar   +1 more source

Characteristics of Children With Invasive Pneumococcal Disease After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine in England and Wales, 2010–2016

The Pediatric Infectious Disease Journal, 2018
Background: In England and Wales, replacement of childhood 7-valent pneumococcal conjugate vaccine (PCV7) with a 13-valent vaccine (PCV13) in 2010 was associated with a significant reduction in PCV13-serotype invasive pneumococcal disease (IPD), with a ...
A. Makwana, C. Sheppard, R. Borrow, N. Fry, N. Andrews, S. Ladhani   +5 more
semanticscholar   +1 more source